The TNM classification of breast cancer: need for change

Denoix PF, Schwartz D (1959) General rules for classification of cancers and presentation of the therapeutic results. Mem Acad Chir (Paris) 85(15–16):415–424 Odicino F, Pecorelli S, Zigliani L, Creasman WT (2008) History of the FIGO cancer staging system. Int J Gynaecol Obstet 101(2):205–210 Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds) (2002) AJCC cancer staging manual, 6th ed. Springer, New York, NY Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM, Henrichs M, Carnicke CL (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249(6):751–757 Leydon GM, Boulton M, Moynihan C, Alison J, Mossman J, Markella B, McPherson K (2000) Cancer Patients’ information needs and information seeking behaviour: in depth interview study. Brit Med J 320(7239):909–913 Costelloe M, Nelson L (2004) The needs of recently diagnosed cancer patients. Nurs Stand 19(13):42–44 Veronesi U, Viale G, Rotmensz Goldhirsch A (2006) Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast 15(1):3–8 Veronesi U, Zurrida S, Viale G, Galimberti V, Arnone P, Nolè F (2009) Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. Breast J 3:291–295 Veronesi U, Zurrida S, Goldhirsch A, Rotmensz N, Viale G (2009) Breast cancer classification: time for a change. J Clin Oncol 27(15):2427–2428 Tavassoli FA (1998) Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 11:140–154 Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553 Veronesi U, Zurrida S, Mazzarol G, Viale G (2001) Extensive frozen section examination of axillary sentinel nodes to determine selective axillary dissection. World J Surg 25(6):806–808 Galimberti V (2006) International breast cancer study group trial of sentinel node biopsy. J Clin Oncol 24(1):210–211 Fernando HC (2008) Radiofrequency ablation to treat non-small cell lung cancer and pulmonary metastases. Ann Thorac Surg 85:S780–S784 Ranjan T, Abrey LE (2009) Current management of metastatic brain disease. Neurotherapeutics 6(3):598–603 Kennedy JE (2005) High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 5(4):321–327 Chiappa A, Makuuchi M, Lygidakis NJ, Zbar AP, Chong G, Bertani E, Sitzler PJ, Biffi R, Pace U, Bianchi PP, Contino G, Misitano P, Orsi F, Travaini L, Trifirò G, Zampino MG, Fazio N, Goldhirsch A, Andreoni B (2009) The management of colorectal liver metastases: expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol 72(1):65–75 Paganelli G, Chinol M (2003) Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 30(5):773–776 Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U (1993) Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 6:1150–1155 Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 18(7):1133–1144 10th St. Gallen conference Curigliano G, Viale G, Bagnardi PV, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Zurrida S, Veronesi P, Goldhirsch A (2009) Clinical Relevance of HER2 Overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693–5699 Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17:1983–1987 Persons DL, Tubbs RR, Cooley LD, Dewald GW, Dowling PK, Du E, Mascarello JT, Rao KW, Wilson KS, Wolff DJ, Habegger-Vance G (2006) HER-2 fluorescence in situ hybridization: Results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 130:325–331 Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D (2006) Correction for chromosome 17 is critical for determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5:2572–2579 Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge OR, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752 Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874